Dr. Maciej Michal Mrugala on the Efficacy and Further Uses of Temozolomide in Gliomas
Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington
Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington’s School of Medicine, discusses the efficacy of temozolomide in gliomas. Mrugala says temozolomide is one of the few treatments that can effectively cross the blood-brain barrier, and is more bioavailable than most other treatments.
Mrugala adds that there are currently ongoing tests to study the efficacy of temozolomide given locally in animal models. He adds there are also studies looking into placing temozolomide into a polymer, which in turn would be placed into the resection cavity as another way of administering treatment.
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
